AML ARISING FROM MYELODYSPLASTIC SYNDROME (MDS)
Clinical trials for AML ARISING FROM MYELODYSPLASTIC SYNDROME (MDS) explained in plain language.
Never miss a new study
Get alerted when new AML ARISING FROM MYELODYSPLASTIC SYNDROME (MDS) trials appear
Sign up with your email to follow new studies for AML ARISING FROM MYELODYSPLASTIC SYNDROME (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for Tough-to-Treat leukemia
Disease control OngoingThis early-stage study tests whether adding AG-120 or AG-221 to standard chemotherapy is safe for people with a specific type of newly diagnosed acute myeloid leukemia (AML) that has an IDH1 or IDH2 mutation. About 153 adults will receive the study drug alongside standard inducti…
Matched conditions: AML ARISING FROM MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated May 26, 2026 12:11 UTC
-
New combo shows promise for Tough-to-Treat leukemia
Disease control OngoingThis study tests whether adding the targeted drug ivosidenib to standard azacitidine helps adults with a specific IDH1-mutated acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy. About 146 participants received either the combo or a placebo plus azaci…
Matched conditions: AML ARISING FROM MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated May 26, 2026 12:04 UTC